NGVTBasic Materials · Specialty ChemicalsThe 3 Wall Street analysts covering Ingevity Corp. hold a median 12-month price target of $86 — +39.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 13 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Ingevity Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (26): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NGVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +39.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 27 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | $65 → $75 |
| 29 Jan 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 19 Dec 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 10 Dec 2025 | BMO Capital | Maintains | Outperform | — |
| 12 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Sept 2025 | BMO Capital | Maintains | Outperform | — |
| 7 Aug 2025 | BMO Capital | Maintains | Outperform | — |
| 14 July 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 7 May 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 9 Apr 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2025 | BMO Capital | Upgrade | Outperform | — |
| 20 Feb 2025 | BMO Capital | Maintains | Market Perform | — |
| 31 Oct 2024 | BMO Capital | Maintains | Market Perform | — |
| 30 Sept 2024 | BMO Capital | Maintains | Market Perform | — |
| 5 Aug 2024 | BMO Capital | Maintains | Market Perform | — |
| 5 Aug 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 1 Aug 2024 | Oppenheimer | Maintains | Outperform | — |
| 11 July 2024 | Wells Fargo | Maintains | Equal-Weight | — |
| 8 May 2024 | BMO Capital | Maintains | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NGVT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Ingevity Corp. returned +22.1% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 11% of US stocks
Cheaper than 52% of US stocks
Cheaper than 3% of US stocks
Cheaper than 42% of US stocks
Higher than 18% of US stocks
Higher than 53% of US stocks
Higher than 55% of US stocks
Higher than 85% of US stocks
Higher than 60% of US stocks
Higher than 90% of US stocks
Higher than 93% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ingevity Corp. has a market value of $2.1B and an enterprise value of $3.2B.
Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter shrank 8.4% year on year.
Net income over the same four quarters: $54.0M, a 4.7% net margin.
Diluted earnings per share, trailing twelve months: $1.47.
Free cash flow in the twelve months to 30 June 2026: $154.9M, after $56.1M of capital spending.
Ingevity Corp. spent $143.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 58.8×; forward P/E: 10.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ingevity Corp. employs 1,400 people — $829K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ingevity Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ingevity reported lower third-quarter sales following a divestiture, while expanding its adjusted profit margin. Executives cited growth in filtration and continued demand from North American hybrid vehicle production.
Why it matters — The results highlight how the divestiture affected sales alongside margin expansion and demand in key areas.
Ingevity held its Q3 2026 earnings call on November 5, 2026, with remarks by CEO David Li and CFO Phillip Platt. The excerpt lists company and analyst participants but provides no earnings results or discussion details.
Why it matters — The call is a company update for NGVT watchers, but the provided excerpt contains no substantive financial or operating information to assess.
Ingevity reported third-quarter earnings of $1.63 per share, above the Zacks Consensus Estimate of $1.56. Earnings were $1.31 per share in the year-ago quarter.
Why it matters — The per-share earnings beat and comparison with the prior-year quarter provide NGVT watchers an update on the company’s quarterly results.
Ingevity Corporation reported its financial results for the third quarter of 2026.
Why it matters — The report provides NGVT watchers with the company’s latest quarterly financial results.
Ingevity announced that CEO Dave Li and members of its leadership team rang the NYSE Closing Bell on October 26, 2026, marking 10 years as a public company. Li described the occasion as a milestone and a celebration of the people behind the company’s progress.
Why it matters — The event marks a corporate milestone that may be of interest to investors following Ingevity’s public-company history and leadership.
The 3 Wall Street analysts covering Ingevity Corp. have a median 12-month price target of $86, with estimates ranging from $85 to $95. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Ingevity Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ingevity Corp. 94 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Ingevity Corp. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +39.4% from the last close, and Ticker Nerd's factor model ranks Ingevity Corp. 94 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ingevity Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $95 over the next 12 months.
Ingevity Corp. returned +22.1% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Ingevity Corporation is a specialty materials and chemical manufacturing company that develops and sells activated carbon products, specialty chemicals, and engineered polymers. Its products are used in emissions control, industrial purification, pavement technologies, adhesives, coatings, resins, elastomers, lubricants, agrochemicals, and other performance applications.
The most recent item we track (MarketBeat, 8 Nov 2026): "Ingevity Q3 Earnings Call Highlights". Ingevity reported lower third-quarter sales following a divestiture, while expanding its adjusted profit margin. Executives cited growth in filtration and continued demand from North American hybrid vehicle production.
Ingevity Corporation is a specialty materials and chemical manufacturing company that develops and sells activated carbon products, specialty chemicals, and engineered polymers. Its products are used in emissions control, industrial purification, pavement technologies, adhesives, coatings, resins, elastomers, lubricants, agrochemicals, and other performance applications. The company serves customers across a broad range of industries, including automotive, infrastructure, water and process treatment, and industrial manufacturing. Ingevity organizes its business around Performance Materials, Performance Chemicals, and Advanced Polymer Technologies, with solutions designed to help customers improve product performance, durability, and process efficiency. Headquartered in North Charleston, South Carolina, Ingevity operates with a global commercial and manufacturing footprint spanning North America, Europe, Asia Pacific, and other international markets.
CEO Mr. David H. Li · 1,400 employees · United States · https://www.ingevity.com
